A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis

NCT02584777 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Primary Myelofibrosis

Interventions

BIOLOGICAL: Pacritinib

Sponsor

Baxalta now part of Shire

Collaborators

[object Object]